{"title":"灵北:在治疗中枢神经系统疾病方面处于领先地位","authors":"","doi":"10.1002/fps.78","DOIUrl":null,"url":null,"abstract":"<p><b>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Lundbeck and its current portfolio, and look at its pipeline of new drugs and areas of research interest.</b></p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 2","pages":"16-18"},"PeriodicalIF":0.0000,"publicationDate":"2011-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.78","citationCount":"0","resultStr":"{\"title\":\"Lundbeck: leading the way in the treatment of CNS disorders\",\"authors\":\"\",\"doi\":\"10.1002/fps.78\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Lundbeck and its current portfolio, and look at its pipeline of new drugs and areas of research interest.</b></p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"12 2\",\"pages\":\"16-18\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.78\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.78\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.78","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Lundbeck: leading the way in the treatment of CNS disorders
This series of company profiles looks at some of the major players in the UK pharmaceutical industry, their current areas of expertise, and forthcoming products and initiatives that will have an impact on therapeutics and prescribing in the near future. In this article we provide an overview of Lundbeck and its current portfolio, and look at its pipeline of new drugs and areas of research interest.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
